Background-Cardiomyopathy is highly heritable but genetically diverse. At present, genetic testing for cardiomyopathy uses targeted sequencing to simultaneously assess the coding regions of >50 genes. New genes are routinely added to panels to improve the diagnostic yield. With the anticipated $1000 genome, it is expected that genetic testing will shift toward comprehensive genome sequencing accompanied by targeted gene analysis. Therefore, we assessed the reliability of whole genome sequencing and targeted analysis to identify cardiomyopathy variants in 11 subjects with cardiomyopathy. Methods and Results-Whole genome sequencing with an average of 37× coverage was combined with targeted analysis focused on 204 genes linked to cardiomyopathy. Genetic variants were scored using multiple prediction algorithms combined with frequency data from public databases. This pipeline yielded 1 to 14 potentially pathogenic variants per individual. Variants were further analyzed using clinical criteria and segregation analysis, where available. Three of 3 previously identified primary mutations were detected by this analysis. In 6 subjects for whom the primary mutation was previously unknown, we identified mutations that segregated with disease, had clinical correlates, and had additional pathological correlation to provide evidence for causality. For 2 subjects with previously known primary mutations, we identified additional variants that may act as modifiers of disease severity. In total, we identified the likely pathological mutation in 9 of 11 (82%) subjects. Conclusions-These pilot data demonstrate that ≈30 to 40× coverage whole genome sequencing combined with targeted analysis is feasible and sensitive to identify rare variants in cardiomyopathy-associated genes. (Circ Cardiovasc Genet. 2014;7:751-759.)
I nherited cardiomyopathy is genetically diverse and has been linked to mutations that are rare in the general population. Genetic testing for cardiomyopathy is a useful adjunct for diagnosis as it is positioned to provide prognostic information for individuals and families. Specific gene mutations may suggest a greater risk of arrhythmias, rapid course, and importantly gene positive individuals with early signs of cardiomyopathy may benefit from early treatment. [1] [2] [3] [4] Currently, clinical genetic testing for cardiomyopathy relies on screening the coding region of multiple genes simultaneously as a gene panel. The first gene panel for cardiomyopathy, introduced in 2007, sampled only 5 genes, whereas current panels assess >50 different genes. 5 Concomitant with panel expansion, sensitivity for mutation identification has increased.
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Massively parallel, next generation sequencing is now being transitioned into the clinical arena. 6 Options include whole exome sequencing (WES) and whole genome sequencing (WGS). WES interrogates only the coding sequence and relies on an exon capture step. This capture step is limited by oligonucleotide design and may be incomplete because of uneven exon capture caused by GC bias, off-target sequencing, and omission of noncanonical transcripts, all especially important in the heart. 7, 8 WES arrays are regularly updated to reflect changes in the annotation of the coding region of the genome. 9 Like panel-based testing, WES may necessitate recapture and resequencing as genome annotation continues. Currently, WES is less expensive than WGS, but that is rapidly changing. High-throughput sequencing technology is now available that can produce high coverage (30×) genomes for $1000.00 (http://www.illumina.com/systems/hiseq-x-sequencing-system.ilmn). This progression in sequencing technology narrows the costs between targeted sequencing and whole genome approaches, making whole genome sequencing a viable alternative to panel sequencing.
The declining cost of WGS and the 100-fold increase in genome coverage makes it a viable alternative to genetic panels and WES for genetic testing of cardiomyopathy. To transition WGS into a useful tool for diagnosing cardiomyopathy requires development of an analytic approach that permits detection of rare mutations. As a first step for cardiomyopathy WGS analysis, we created a super gene set with 204 known and putative cardiomyopathy genes. This super gene set exceeds the number of genes on most clinically available gene panels for cardiomyopathy because the super gene set was extended based on association with cardiomyopathy in humans and animal-based modeling. WGS data were filtered through this super gene set to determine the feasibility of using WGS as a reliable screening method for cardiomyopathy variants. To test the sensitivity of WGS combined with this analytic approach, it was tested in 11 unrelated subjects with dilated cardiomyopathy (DCM). The pathogenic or likely pathogenic variants were identified in 9 of 11 subjects (82% detection rate). These data demonstrate that ≈30 to 40× coverage WGS is a reliable alternative to panel-based testing for cardiomyopathy. Furthermore, for those individuals in which the super gene set was unrevealing, the remaining genome sequence is available for immediate further interrogation, instead of waiting for additional panel-based testing justifying the extracost and time associated with WGS.
Methods

Study Subjects
Eleven unrelated subjects with nonischemic DCM were selected for WGS. Personal and family history of cardiomyopathy were available for all subjects. The study was approved by the University of Chicago Institutional Review Board. All study subjects provided written informed consent. Genetic counseling for WGS was provided.
Generation of Whole Genome Sequence Data
Genomic DNA was extracted from the peripheral blood of 10 study subjects and the explanted heart tissue of 1 subject. Reversible terminator massively parallel sequencing was performed by Illumina (San Diego, CA) on the HiSeq2000. Paired end reads were mapped to the National Center for Biotechnology Information reference genome 37.1 (hg19) and variants were called using Illumina's proprietary software (ELAND/CASAVA).
Myopathy Super Gene Set
The myopathy gene set comprises 204 genes (245 transcripts) identified by published association with cardiac or skeletal myopathies or cardiac arrhythmias as a single gene disorder, association-based study, or in animal models. In genes with multiple transcripts, those transcripts with the highest expression in cardiac and skeletal muscle were included in the gene set. For all transcripts in the gene set, exonic boundaries ±10 base pairs (bps) were downloaded from the Ensemble Genome Browser (http://useast.ensembl.org/index.html).
Analysis of Protein Coding Single Nucleotide Variants
The effect of single nucleotide variants (SNVs) was determined using SeattleSeq Annotation 134 (http://snp.gs.washington.edu/ SeattleSeqAnnotation134/). Variants were analyzed using PolyPhen-2 (PP2), Sorting Tolerant From Intolerant (SIFT), PhastCons, Genomic Evolutionary Rate Profiling (GERP), Protein analysis through evolutionary relationships (Panther), and ConSeq. [10] [11] [12] [13] [14] [15] Frequency was assessed using 3 publically available databases: The March, 2012 Integrated Phase 1 release of the 1000 Genomes Project, 16 the National Heart, Lung, and Blood Institute Exome Sequencing Project (ESP 5400) (http://evs.gs.washington.edu/EVS/), and dbSNP 135/136 (http://www.ncbi.nlm.nih.gov/projects/SNP/). A minor allele frequency of ≤0.01 was used to restrict variants.
Prioritization of Intronic SNVs
Variants were analyzed by MaxEntScan using publically available perl scripts. 17 Retained variants were then analyzed for frequency using the March, 2012 Integrated Phase 1 release of the 1000 Genomes Project 16 and dbSNP 135/136 (http://www.ncbi.nlm.nih. gov/projects/SNP/).
Identification and Analysis of Insertion/Deletion Polymorphisms
Insertions/deletions (Indels) were annotated using the Variant Effect Predictor (http://useast.ensembl.org/index.html). Indels in the coding sequence or at a splice junction were scored for frequency using the 1000 Genomes Project. 16 
Desmin Expression
Full-length human desmin cDNA (Origene) was mutated. Wild-type and mutant plasmid was placed into pcDNA3.1/His C (Invitrogen) and transfected into C2C12 cells (ATCC) grown in DMEM supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin in a 10% CO 2 incubator at 37°C. After 48 hours, cells were fixed in 100% methanol (−20°C) and stained as described using an anti-Xpress Antibody (Invitrogen). Results were imaged as described. 18
Results
Eleven unrelated subjects with nonischemic cardiomyopathy ( Table 1) were selected for WGS and targeted analysis. Nine of the 11 subjects or an affected family member had undergone previous panel-based clinical genetic testing ( Table 1) . The number of genes assessed by this previous testing varied with the year in which the subject had undergone testing. In 3 of the 9 subjects who had undergone clinical testing, a pathogenic mutation was found via clinical testing (Table 1) . WGS was performed in these families to provide validation to confirm that WGS has sensitivity to detect known mutations. Also, 2 of the families (DCM-AAB and DCM-Bl) exhibited marked phenotypic variability between generations. In these families the probands required heart transplant in the second decade of life, whereas other family members, carrying the clinically identified mutation, were only mildly affected into the fourth decade of life. These data suggested additional genetic modifiers. For 6 of 9 subjects previous clinical genetic testing was unrevealing. WGS was completed with an average coverage of 37.1-fold. On average, 113.4 GB of data per individual passed filter (Q≥20) and aligned to the reference genome covering 97.9% of the non-N reference genome ( Table I in the online-only Data Supplement). We restricted our analysis to a super gene set that included 204 genes (245 transcripts) previously associated with Mendelian or non-Mendelian forms of cardiomyopathy, skeletal myopathies, or cardiac arrhythmias as demonstrated in either humans or animal models ( Table II in the online-only Data Supplement).
Analysis of SNVs
WGS identified an average of 3.7 million SNVs per individual with a greater number of SNVs identified in the 2 non-white individuals (4.0 million). Each genome had ≈11 586 nonsynonymous SNVs. Restricting analysis to the super gene set reduced the average number of missense SNVs to 167 per individual ( Table III in the online-only Data Supplement). Missense SNVs were filtered using a combination of algorithms that predict effect based on conservation and structure.
SNVs were identified as rare based on their frequency in the population at large ( Figure 1 ). For TTN, only truncating variants were considered as described by Herman et al, 19 as is the standard practice for clinical genetic testing. Missense variants in TTN were not considered because these variants are highly prevalent in the general population and vastly exceed the frequency of cardiomyopathy, making them difficult to interpret at this time. 20 Variants common to multiple individuals in the sequencing cohort and absent from frequency databases were discarded as they represent sequencing or aligning artifacts. This analysis pipeline reduced the number of potentially damaging missense variants to 0 to 11 per individual ( Table IV in the online-only Data Supplement). Variants were confirmed using Sanger Sequencing. We tested the sensitivity of this pipeline using 100 independent mutations reported in inherited cardiomyopathy and found it to be 91% sensitive ( Table V in the online-only Data Supplement). We also detected the one known pathogenic missense mutation previously identified in the cohort in subject DCM-AAB03 (TPM1 D230N).
To assess variants positioned to alter splicing, SNVs within 10 bps of exon boundaries were filtered through maximum entropy and evaluated for frequency in the population at large ( Figure 1 ). MaxENT estimates the strength of the 5′ and 3′ splice junctions using a maximum entropy model. 17 An average of 50 intronic SNVs (range, 44-63) was identified in each individual using the super gene set. Filtering with MaxENT reduced this list to ≤4 per individual. By including only rare variants, the number of splice site altering SNVs was reduced to 0 to 2 per individual ( Table IV in the online-only Data Supplement). Variants were confirmed using Sanger Sequencing. We tested the sensitivity of this approach using a control data set of 25 known splice site altering mutations and found it to be 88% sensitive ( Table V in the online-only Data Supplement). This approach also detected the single known splice variant within the cohort in MDC-01 (DES c.735+3 A>G); this variant was previously shown to disrupt splicing. 21, 22 Combining the analyses for missense, nonsense, and splicing variants produced 1 to 13 potentially pathogenic SNVs per individual ( Table IV in the online-only Data Supplement). All variants that passed pipeline criteria were then manually curated based on the specific phenotype of the proband. For example, variants in genes that are usually associated with muscle involvement were ranked lower in probands without muscle disease. Variants were then tested for segregation, where possible ( Table 2 ).
Analysis of Indel Polymorphisms
Each genome had on average 293 729 insertions and 312 947 deletions. Filtering these variants using the super gene set reduced the number to ≈88 indels per individual ( Table  III in the online-only Data Supplement). Indels in the coding sequence or at a splice junction and present in the 1000
Genomes database at frequency ≤0.01 were retained. Indels common in the sequenced cohort were omitted as these are likely sequencing/aligning artifact. This analysis reduced the number of potentially pathogenic indels to 0 to 1 per individual, which were confirmed using Sanger Sequencing. This analysis also detected the single known pathogenic indel within the cohort in DCM-BI01 (TNNT2 K210del). Combining the analysis for ndels with that for SNVs produced 1 to 14 potentially pathogenic variants per individual. Missense single nucleotide variants (SNVs) from these genes were analyzed using PolyPhen-2, SIFT, PhastCons, and GERP. [10] [11] [12] [13] Variants were retained if predicted to be probably or possibly damaging by PolyPhen-2 or if damaging by 2 of the 3 remaining programs. Cutoff scores of 0.95 and 3 were considered damaging by PhastCons and GERP, respectively. If no prediction was made by at least 3 of 4 programs, the variant was retained for further analysis. Variants were then analyzed by Panther and ConSeq. 14, 15 Variants with a Panther substitution positionspecific evolutionary conservation score of <−2 or a ConSeq score <0 were retained. If neither program was able to make a prediction, the variant was retained. This filtering reduces the number of variants to ≈167 per genome. Variants were analyzed for frequency using 3 databases: the 1000 Genomes Project, National Heart, Lung, and Blood Institute Exome Sequencing Project (ESP 5400), and dbSNP 135/136. 16 Variants present at a frequency of ≤0.01 were retained, resulting in 0 to 11 nonsynonymous single nucleotide variant per genome. Nonsense SNVs within the myopathy super gene set were filtered using frequency. B, Splice site variant analysis. Analysis was restricted to intronic SNVs within 10 bp of an exon, reducing variant lists from ≈3.7 mol/L to 50 per genome. Variants were analyzed using maximum entropy. 17 The 1000Genomes Project and dbSNP 135/136 were used to determine frequency. Variants present at a frequency of ≤0.01 were deemed potentially deleterious, resulting in 0 to 2 variants per genome. 
Likely Pathogenic Cardiomyopathy Variants Detected by WGS
Potentially pathogenic variants were filtered based on the genes' tissue expression pattern, association with syndromic features, and pattern of inheritance. Candidate variants were confirmed by Sanger sequencing and sequenced in family members for segregation when available. We identified 11 likely pathogenic mutations in 9 individuals, including 9 new mutations not identified by traditional panel-based screening ( Table 2; Tables VII-XIII in the online-only Data Supplement) . Of these mutations, 2 are second mutations identified within an individual that may function as disease modifiers. For 7 subjects, segregation analysis was performed in 2 to 38 family members, including both affected and unaffected individuals ( Table 2 ; Figures I-IV in the online-only Data Supplement). Subject DCM-BH01 presented at the age of 62 years with nonischemic DCM, nonsustained ventricular tachycardia, and a wide QRS complex consistent with cardiac conduction system disease (Figure 2A) . Clinical genetic testing for 20 DCM genes was negative ( Table 1 ). WGS identified 3 potentially pathogenic variants, including missense variants in SCN5A, FKTN, and HPS6 ( Figure 2B ). Both HPS6 and FKTN were excluded because of association with syndromic, autosomal recessive disorders. 23, 24 The SCN5A G1318V variant was absent from public databases. SCN5A mutations near this region have been linked to both DCM and inherited arrhythmic disorders, 25 consistent with the striking conduction system disease observed in this individual. 26 The SCN5A G1318V variant was also found in an adult offspring whose left ventricular (LV) ejection fraction was 47.8% ( Figure 2C ).
An SCN5A variant was also identified in subject SD-303 ( Figure I in the online-only Data Supplement). SD-303 has a history of arrhythmias beginning in the third decade of life. Congestive heart failure was diagnosed in the sixth decade of life and a heart transplant was performed at the age of 61 years. Family history is remarkable for arrhythmia, sudden death, and congestive heart failure with some family members requiring transplant before the age of 40 years. WGS identified 7 potentially pathogenic variants, all missense (Table VII in the online-only Data Supplement). Segregation analysis of SCN5A R814W in 16 family members confirmed its association with disease ( Figure I in the online-only Data Supplement). SCN5A R814W was both rare and considered highly deleterious by all algorithms. This particular variant has also been described as a de novo mutation in a 23-year-old woman with sporadic DCM, atrial flutter, and short runs of nonsustained ventricular tachycardia. 27 Nguyen et al 28 found that the SCN5A R814W mutation disrupted both activation and deactivation of Na v 1.5.
Subject DCM-AAL01 was diagnosed with DCM at the age of 32 years and underwent heart transplantation at the age of 43 years ( Figure 3A) . Clinical genetic testing was negative for 11 genes (Table 1) . Seven potentially pathogenic missense variants were identified in the myopathy super gene set ( Table VIII in the online-only Data Supplement). Variants in LDB3, MYH11, and DES were identified as potentially relevant based on the proband's phenotype and were confirmed by Sanger sequencing (Figure 3B ). The variant in MYH11 is unlikely to be the primary driver because MYH11 variants are often associated with aortic aneurysm, which was not a factor in this subject's disease. 29, 30 We performed immunohistochemical staining for desmin and electron microscopy on frozen sections from the proband's explanted heart. Desmin aggregates were readily evident, diagnostic of a desminrelated myopathy ( Figure 3C ). 31, 32 Segregation analysis could not be performed as all affected family members had died or were unavailable for testing. Epitope-tagged DES R127P or wild-type desmin was introduced into myogenic C2C12 cells to assess pathogenicity. Intracellular desmin aggregates were readily detected with DES R127P but not with wildtype desmin, confirming the pathogenicity of this variant ( Figure 3D ). LDB3, also known as ZASP or CYPHER, has been linked to cardiomyopathy and, given the variant's rarity, may contribute to the phenotype. 33 As desmin protein aggregates were observed in the subject's explanted heart, and as these aggregates are not known to be a feature of LDB3 mutations, these data lead us to conclude that DES is the primary genetic mutation in this individual. Genetic counseling was provided to the subject. FKTN and HPS6 were excluded as these genes are linked to recessive, syndromic disease. 23, 24 The SCN5A G1318A variant was considered pathogenic because SCN5A gene mutations are known to affect the cardiac conduction system in addition to causing DCM. 26 C, SCN5A G1318A variant was identified in the proband's offspring with DCM. NHLBI ESP indicates National Heart, Lung, and Blood Institute Exome Sequencing Project. December 2014
Whole Genome Sequencing Identifies Second Hits as Disease Modifiers
WGS and the super gene set were applied to 2 families that displayed a range of phenotype, consistent with disease modifiers. The first was an individual with a known TPM1 mutation with a more severe clinical course compared with other affected family members ( Figure 4A ). Subject DCM-AAB03 underwent heart transplantation at the age of 20 years after presenting with refractory heart failure symptoms and severe LV systolic dysfunction (LV ejection fraction <20%). With the exception of 1 brother who died from cardiomyopathy and muscle weakness at the age of 12 years, other family members remain only mildly affected into the fourth decade and beyond. WGS identified 6 potentially pathogenic missense mutations, including a mutation in the X-encoded GLA gene ( Table IX in the online-only Data Supplement). Mutations in GLA, which codes for the protein β-galactosidase-α, cause the X-linked disorder Fabry disease. 34, 35 DCM-AAB03 was hemizygous for the GLA R118C variant while his less severely affected sisters and mother were heterozygous for the variant and his more mildly affected brother carried only the primary mutation in TPM1.
The second family was known to have a primary TNNT2 mutation but evidence for variability. Specifically, subject DCM-BI01 presented at the age of 16 years with a LV ejection fraction of 9.8% and underwent cardiac transplantation ( Figure 4B ). Clinical genetic testing identified TNNT2 K210del as a pathogenic mutation. The TNNT2 K210del mutation was also detected using the filtering pipeline for WGS. Both the patient and his brother, who also required heart transplantation in adolescence, carry the TNNT2 K210 deletion. This mutation was also found in the subject's affected mother and in his mildly affected grandmother, who at the age of 65 years had asymptomatic LV dysfunction (LV ejection fraction 45%). This phenotypic variability has been noted previously with the TNNT2 K210del variant. [36] [37] [38] WGS also identified a TTN splice variant c.42521-5 G>C (Table X in the onlineonly Data Supplement). This variant was found in the 2 boys who required heart transplants in their second decade but not in their grandmother who was only mildly affected at the age of 65 years ( Figure 4B ). This TTN splice variant has a MaxEnt score of 5.97, which is deleterious by the criteria set forth by Herman et al 19 for TTN splice sites.
Discussion
WGS Detects Rare Variants for Cardiomyopathy
WGS offers a comprehensive approach to identifying genetic variation across the genome. We now show that rare variants can be detected in cardiomyopathy genes using WGS and targeted analysis. Although the comprehensive nature of WGS or even WES is attractive, analytic tools must be refined to identify pathogenic variants. The pipeline applied herein relied on (1) restricting the number of genes for analysis to a super gene set, (2) filtering based on frequency with the assumption that a rare disease is caused by rare genetic variation, and (3) protein prediction algorithms that largely rely on disrupting conserved regions. The method successfully identified 3 known mutations (DES c.735+3 A>G in patient MDC-01, TNNT2 K210del in patient DCM-Bl01, TPM1 D230N in patient DCM-AAB03) providing proof of principle that WGS at 30 to 40× coverage is sensitive to detect these rare variants. Likely pathogenic variants were identified in 6 of the remaining patients. Each proband had 1 to 14 variants that passed filtering criteria of our pipeline. We relied on segregation analysis, functional data, and phenotypic data from each subject to further refine the variant list. It is important to note that phenotypic information is invaluable when identifying likely pathogenic variation and that manual curation of each high probability variant is required.
In subject DCM-AAY02, a putative mutation in the gene encoding γ-filamin, also known as filamin C (FLNC), was found ( Table 2 ; Table XI in the online-only Data Supplement). DCM-AAY02 presented at the age of 57 years with left anterior hemiblock and intraventricular conduction delay, but without skeletal muscle disease. FLNC encodes an actin-crosslinking protein that interacts with the dystrophin-associated protein complex, and mutations in FLNC lead to skeletal myopathy in humans and mice. 39, 40 Moreover, a fish model, medaka, with reduced FLNC expression, resulted in an enlarged and mechanically weakened heart. 41 Furthermore, a quantitative proteomic assessment of aggregates in desminopathy identified filamin C as the second most abundant protein in these aggregates, providing additional support for the role of filamin C as a mediator of cardiomyopathy. 42 The FLNC mutation identified in DCM-AAY02 is located 1 bp from a splice acceptor, is absent from the 1000 Genomes database, is predicted to be strongly deleterious by MaxENT, and is not present in an unaffected sibling. Although further functional studies are required to confirm the pathogenicity of this variant, these data underscore the use of having a mutable super gene set that allows for the interrogation of putative cardiomyopathy genes.
Perhaps the greatest value of broad-based sequencing is the capacity to further interrogate the data if a mutation is not identified on first pass analysis. Here, the super gene set is defined by genes previously associated with cardiomyopathy, restricting our ability to identify new cardiomyopathy-associated genes. The super gene set is mutable and genes can be added and removed at any time, allowing for the identification of variation in genes that may be suspected in the pathogenesis of cardiomyopathy. Analysis can be rerun in minutes to hours depending on the size of the data set. However, this approach is candidate driven and will not identify variation in genes not on the super gene set. Additional panel-based testing can take weeks to months to complete and may still not supply variants of interest. Furthermore, as WGS becomes more commonplace, it is possible that patients will already have sequencing data. Although panel-based testing is generally higher coverage, this pilot study confirms that 30 to 40× coverage sequencing data are appropriate for identifying cardiomyopathy mutations.
For 2 subjects in this pilot study, WGS did not identify a clear mutation. We expect that these 2 individuals have mutations in genes outside the super gene set. Importantly, the available WGS sequence from these genomes will permit ongoing analysis and will not require reinvestment in additional sequencing. Larger gene panels have increased sensitivity for mutation detection, especially for DCM. Therefore, it can be expected that having comprehensive sequencing should have even greater power to detect primary mutations, and importantly secondary modifier mutations, which may account for disease severity or point to potentially treatable disorders such as cardiomyopathy amenable to enzyme replacement therapy like Fabry. 43
Cost Considerations
The cost of targeted panel sequencing, whole exome, and whole genome sequencing is a major consideration, and costs are shifting rapidly with new technology. Clinical testing for cardiomyopathy using targeted panel sequencing is around $4000 at this time. Current pricing for clinical exome sequencing is ≈$7000 but varies widely depending on the extent of The TPM1 D230N variant segregates with cardiomyopathy in all family members. Several members of this family had earlier onset disease. Individual II-3 presented at the age of 20 years with heart failure and was found to be hemizygous for the X-linked GLA R118C variant. B, DCM-BI01 pedigree. The TNNT2 K210del variant has been described previously in cardiomyopathy. 33, 38 The 2 younger members who required cardiac transplantation had an additional TTN mutation predicted to disrupt the splice site and truncate TTN. variant analysis. Clinical whole genome sequencing is ≈$9000 to 9500, and like other clinical genetic testing costs includes the cost of analysis. The anticipated $1000 genome is for researchbased studies and does not include the cost of analysis. Sequencing depth is also a major consideration for sequencing studies. Next generation sequencing technologies have a higher per base sequencing error than traditional Sanger sequencing reducing the probability of true-positive variants. 44 The higher error rate requires higher depth whereby each base is sequenced X number of times by high-quality reads. However, as depth increases so does cost. In this study, WGS was performed at 30 to 40× because previous work has shown that readable bases and number of SNVs identified increases exponentially with increasing depth, with a plateau at 30×, indicating diminishing returns with additional sequencing. 45 It is also important to note that sequencing reads should undergo extensive filtering to identify and discard low-quality reads. It is imperative that analysis pipelines be applied to sequencing data to control for faulty reads, misalignment to the referent genome, and low-quality variant calls. These steps contribute to analysis costs. Given the range of approaches used for bioinformatics, costs for analysis will vary widely. Reducing analytic costs will derive from improving alignment and variant calling pipelines as well as refining which genes to analyze and automating pipelines to reduce human analytic time. The informatically designed super gene set, which was applied here to WGS, is expected to be refined to provide more specific results. The use of this approach is that the super gene set is virtual, and as such the analysis can readily be updated and optimized without the need for recapture and resequencing. Thus, for those individuals for which a primary mutation is not identified, the remaining genome information is available for analysis. These data provide a wealth of information that may inform not only about new genes that cause cardiomyopathy but also about combinations of genes that may provide important prognostic information.
